Delivery Order SPE2DB20D3104-SPE2DB25FW0B1
- Not listed
- The Defense Logistics Agency awarded a $3,712.29 firm fixed price delivery order to AmerisourceBergen Drug Corp for Naloxone HCl 4 mg nasal spray (2-pack units) with an ultimate completion date of August 1, 2025. This non-set-aside contract was awarded competitively and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical will be delivered to the contractor's location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order valued at $1,889.41 to AmerisourceBergen Drug Corp for Naloxone HCl 4 mg nasal spray (2-unit package). This competitively awarded, firm fixed-price contract was issued on September 4, 2025, with an ultimate completion date of September 5, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery...
- The Defense Logistics Agency awarded a delivery order valued at $3,580.96 to AmerisourceBergen Drug Corp for Naloxone HCL 4 mg nasal spray (2-count units) on August 18, 2025, with completion scheduled for August 19, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime contract vehicle running through December 2026 that supplies...
- The Defense Logistics Agency awarded a delivery order valued at $1,004.16 to AmerisourceBergen Drug Corp for Naloxone HCL 4 mg nasal spray (2-pack units) on July 28, 2025, with completion scheduled for July 29, 2025. This non-set-aside, firm fixed-price delivery order represents a small-value transaction under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical support vehicle running through...
- The Defense Logistics Agency awarded a delivery order valued at $1,124.16 to AmerisourceBergen Drug Corp for Naloxone HCL 4 mg nasal spray (2-count units) on August 22, 2025, with completion scheduled for August 25, 2025. This firm fixed price contract was awarded competitively with no set-aside designation and is being performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,572.48 to AmerisourceBergen Drug Corp for Naloxone HCL 4 mg nasal spray (2-count units) on September 3, 2025, with an ultimate completion date of September 4, 2025. This firm fixed-price delivery order, issued without set-aside designation, represents a competitively awarded transaction under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (contract SPE2DX), valued at...
- The Defense Logistics Agency awarded a delivery order valued at $1,928.40 to AmerisourceBergen Drug Corp for Naloxone HCl 4 mg nasal spray (2-count units) on August 22, 2025, with an ultimate completion date of August 25, 2025. This firm fixed-price, non-set-aside contract is classified as a child award, indicating it derives from a larger contract vehicle. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a $1,653.49 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Naloxone HCL 4 mg nasal spray (2-count units). The contract, which was competitively awarded with no set-aside designation, is scheduled for completion by August 5, 2025, and will be performed at the awardee's Conshohocken, Pennsylvania location. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $11,472.11 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Naloxone HCL 4 mg nasal spray (2-count units). This is a non-set-aside contract with an ultimate completion date of August 12, 2025, and represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency awarded a delivery order valued at $1,301.63 to AmerisourceBergen Drug Corp for the supply of Naloxone HCL 4 mg nasal spray (2-pack units) on July 23, 2025, with completion required by July 24, 2025. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.99 billion comprehensive pharmaceutical supply vehicle running through December 2026. The...
- SPE2DB20D3104Indefinite Delivery Contract
- SPE2DB20D3104-SPE2DB25FW0B1Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $12,167.80 to AmerisourceBergen Drug Corp for Naloxone HCl 4 mg nasal spray on September 9, 2025, with completion scheduled for September 10, 2025. This firm fixed price contract represents a non-competitive set-aside and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion vehicle valued through December 2026 that serves as a comprehensive pharmaceutical support mechanism for military healthcare programs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, regularly fulfills federal medical supply requirements through the Defense Logistics Agency's Medical Supply Chain. The company maintains an extensive portfolio of pharmaceutical products and medical supplies across multiple therapeutic domains, ranging from brand-name and generic medications to vaccines and specialized medical devices. This naloxone award reflects the company's ongoing role as a critical vendor supporting military healthcare systems and other federal government healthcare entities, consistent with its track record of competitively awarded delivery orders under firm fixed pricing structures.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.2k | 9/9/25 |